Nuvo Cares Secures $30M Series A to Revolutionize Prenatal Care with INVU™️

Nuvo Cares is excited to announce that it has raised $30 million in its latest funding round, a major milestone that will accelerate its mission of advancing prenatal care through innovative technology. As a healthcare technology leader, Nuvo is revolutionizing maternal-fetal health monitoring with its flagship product, INVU by Nuvo™️, an FDA and CE-approved, AI-driven remote monitoring platform. Recognized among TIME's Best Inventions of 2024, INVU seamlessly collects vital biometric data such as fetal heart rate (FHR), maternal heart rate (MHR), and uterine activity, empowering clinicians to monitor high-risk pregnancies in unprecedented ways. This funding will be directed toward further enhancing the platform’s capabilities, expanding its reach in the healthcare sector, and enabling more healthcare providers to leverage remote fetal non-stress tests (NSTs) that streamline clinical workflows, improve protocol adherence, and increase operational efficiency. For expecting mothers, the groundbreaking technology means the comfort of performing NSTs from home or work—eliminating the need for travel, reducing waiting times, and easing childcare challenges—while saving up to 12 hours throughout their pregnancy. With the additional capital, Nuvo Cares plans to invest in advanced AI research to help clinicians detect early signs of complications, including placental insufficiency, intrauterine growth restriction (IUGR), and fetal distress, and to further scale market access to underserved communities. The infusion of $30 million marks a pivotal step in transforming prenatal care by leveraging state-of-the-art wearable sensors, cloud-based data processing, and intuitive software applications for both clinicians and mothers, ultimately setting a new standard for quality and accessible prenatal care.